Stock 2005 SSY GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SSY Group Limited

Equities

2005

KYG8406X1034

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:06 30/04/2024 BST 		5-day change 1st Jan Change
4.78 HKD +0.21% Intraday chart for SSY Group Limited +0.63% -3.24%
04-23 SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator MT
04-16 SSY Group Logs Nearly 15% Boost in Q1 Profit MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SSY GROUP LIMITED Stock SSY Group Limited
-3.24% 1.81B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.95% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.89% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2005 Stock
  4. Ratings SSY Group Limited